Nadroparin calcium
| Systematic (IUPAC) name | |
|---|---|
|
(4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
|
|
| Clinical data | |
| Trade names | Fraxiparine, Fraxodi |
| AHFS/Drugs.com | International Drug Names |
| Legal status | |
| Routes of administration |
SC (except for haemodialysis) |
| Pharmacokinetic data | |
| Bioavailability | 89% (SC dose) |
| Biological half-life | 3.7 hours (SC dose) |
| Excretion | clearance 21.4mL/min (+/- 7) |
| Identifiers | |
| CAS Number | 9041-08-1  |
| ATC code | B01AB06 (WHO) |
| DrugBank | DB08813 |
| KEGG | D07510 |
| Chemical data | |
| Molecular mass | 4300 g/mol |
 (what is this?) (verify) |
|
Nadroparin (trade name, Fraxiparine or Fraxodi) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by sanofi-synthelabo.
Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction. [1]
For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the stomach. Injections are given once or twice daily depending on the condition.[1]
References
- ↑ 1.0 1.1 Fraxiparine PRODUCT MONOGRAPH (Canada); http://www.aspripharma.com/pdf/Fraxiparine%20&%20Fraxi%20Forte%20PM_EN.pdf
External links
- http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128
- http://www.mayoclinic.com/health/drug-information/DR600971
- Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
